-
EP2186824
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2186824
| EP2186824 - Chronic treatment regimen using glucagon-like insulinotropic peptides [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 09.09.2011 Database last updated on 24.01.2025 | Most recent event Tooltip | 09.09.2011 | Application deemed to be withdrawn | published on 12.10.2011 [2011/41] | Applicant(s) | For all designated states Eli Lilly & Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2010/20] | Inventor(s) | 01 /
Dodd, Steven Witt 6541 Stafford Trace Zionsville, IN 46077 / US | 02 /
Mace, Kenneth Francis 10907 Killington Circle Fishers, IN 46038 / US | 03 /
Trautmann, Michael Ernst Lilly Deutschland Saalburgstrasse 153 Bad Homburg 61350 Hamburg / DE | [2010/20] | Representative(s) | Kent, Lindsey Ruth Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [N/P] |
| Former [2010/20] | Kent, Lindsey Ruth Eli Lilly and Company Limited Lilly Research Center Erl Wood Manor Sunninghill Road Windlesham Surrey GU20 6PH / GB | Application number, filing date | 08151437.4 | 07.12.2001 | [2010/20] | Priority number, date | US20000255251P | 13.12.2000 Original published format: US 255251 P | US20010295655P | 04.06.2001 Original published format: US 295655 P | US20010298652P | 15.06.2001 Original published format: US 298652 P | [2010/20] | Previously filed application, date | WO2001US44698 | 07.12.2001 | [2010/20] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP2186824 | Date: | 19.05.2010 | Language: | EN | [2010/20] | Type: | A3 Search report | No.: | EP2186824 | Date: | 22.09.2010 | [2010/38] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 19.08.2010 | Classification | IPC: | C07K14/605, C30B7/00, C07K1/30, A61K38/26 | [2010/20] | CPC: |
A61K38/2278 (EP,US);
A61P1/00 (EP);
A61P3/04 (EP);
A61P3/10 (EP);
A61P9/00 (EP);
A61P9/10 (EP);
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2010/20] | Title | German: | Chronisches Behandlungsschema mit Glucagon-ähnlichen insulinotropischen Peptiden | [2010/20] | English: | Chronic treatment regimen using glucagon-like insulinotropic peptides | [2010/20] | French: | Posologie de traitement chronique à l'aide de peptides insulinotropiques de type glucagon | [2010/20] | Examination procedure | 22.03.2011 | Examination requested [2011/17] | 08.04.2011 | Application deemed to be withdrawn, date of legal effect [2011/41] | 17.05.2011 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time [2011/41] | Parent application(s) Tooltip | EP01987138.3 / EP1390061 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20010987138) is 06.12.2006 | Fees paid | Renewal fee | 16.06.2008 | Renewal fee patent year 03 | 16.06.2008 | Renewal fee patent year 04 | 16.06.2008 | Renewal fee patent year 05 | 16.06.2008 | Renewal fee patent year 06 | 16.06.2008 | Renewal fee patent year 07 | 05.01.2009 | Renewal fee patent year 08 | 04.01.2010 | Renewal fee patent year 09 | 03.01.2011 | Renewal fee patent year 10 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X] - KOLTERMAN O ET AL, "FIVE-DAY DOSING OF SYNTHETIC EXENDIN-4 (AC2993) IN PEOPLE WITH TYPE2 DIABETES REDUCES POST-PRANDIAL GLUCOSE, GLUCAGON AND TRIGLYCERIDE CONCENTRATIONS", DIABETOLOGIA, SPRINGER, BERLIN, DE, (20000101), vol. 43, no. SUPPL. 01, ISSN 0012-186X, page A189, XP000993160 [X] 1,4,15 * abstract * | [X] - KOLTERMAN O ET AL, "DOSE-RESPONSE FOR INHIBITION OF GLUCAGON SECRETION AND GASTRIC EMPTYING BY SYNTHETIC EXENDIN-4 (AC2993) IN SUBJECTS WITH TYPE 2 DIABETES", DIABETES, AMERICAN DIABETES ASSOCIATION, US, (20000501), vol. 49, no. SUPPL. 01, ISSN 0012-1797, page 460, XP000938453 [X] 1,4,15 * abstract * | [X] - L B KNUDSEN ET AL., "Potent derivatives of glucagon-like peptide 1 with pharmacokinetic properties suitable for once daily administration", JOURNAL OF MEDICINAL CHEMISTRY., AMERICAN CHEMICAL SOCIETY., (20000504), vol. 43, no. 9, ISSN 0022-2623, pages 1664 - 1669, XP002201014 [X] 1-17,25,26 * the whole document * DOI: http://dx.doi.org/10.1021/jm9909645 | [X] - N H GREIG ET AL., "Once daily infection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentration", DIABETOLOGIA, SPRINGER, (199901), vol. 42, no. 1, ISSN 0012-186X, pages 45 - 50, XP000971927 [X] 1-13,19-32 * the whole document * DOI: http://dx.doi.org/10.1007/s001250051111 | [A] - C F DEACON ET AL., "Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide -1 which have extended metabolic stability and improved biological activity", DIABETOLOGIA, SPRINGER, (199801), vol. 41, no. 1, ISSN 0012-186X, pages 271 - 278, XP000917648 [A] 1-15,25,26 * the whole document * DOI: http://dx.doi.org/10.1007/s001250050903 |